BioStock: Biosergen’s CEO: “These findings open up new possibilities”

Biosergen’s antifungal drug candidate, BSG005, continues to show strong clinical potential. The majority of the patients in the second cohort either fully recovered or significantly improved, consistent with earlier results. With these encouraging outcomes, Biosergen is advancing key regulatory and development plans for BSG005. BioStock reached out to CEO Tine Olesen to get her comments on this achievement.
“Every opportunity to gain time or market share is being thoroughly explored”, says Tine.

Read the interview with CEO Tine Olesen at biostock.se:

https://www.biostock.se/en/2025/02/biosergens-ceo-these-findings-open-up-new-possibilities

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/